Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver

Shu‐Hao Hsu(The Ohio State University), Bo Wang(The Ohio State University), Janaiah Kota(Nationwide Children's Hospital), Jianhua Yu(The Ohio State University), Stefan Costinean(The Ohio State University), Huban Kutay(Comprehensive Blood & Cancer Center), Lianbo Yu(The Ohio State University), Shoumei Bai(University of Michigan), Krista La Perle(The Ohio State University), Raghu R. Chivukula(Johns Hopkins University), Hsiaoyin Mao(Comprehensive Blood & Cancer Center), Wei Min(Comprehensive Blood & Cancer Center), K. Reed Clark(Nationwide Children's Hospital), Jerry R. Mendell(Nationwide Children's Hospital), Michael A. Caligiuri(Comprehensive Blood & Cancer Center), Samson T. Jacob(Comprehensive Blood & Cancer Center), Joshua T. Mendell(Southwestern Medical Center), Kalpana Ghoshal(The Ohio State University)
Journal of Clinical Investigation
July 23, 2012
Cited by 779Open Access
Full Text

Abstract

miR-122, an abundant liver-specific microRNA (miRNA), regulates cholesterol metabolism and promotes hepatitis C virus (HCV) replication. Reduced miR-122 expression in hepatocellular carcinoma (HCC) correlates with metastasis and poor prognosis. Nevertheless, the consequences of sustained loss of function of miR-122 in vivo have not been determined. Here, we demonstrate that deletion of mouse Mir122 resulted in hepatosteatosis, hepatitis, and the development of tumors resembling HCC. These pathologic manifestations were associated with hyperactivity of oncogenic pathways and hepatic infiltration of inflammatory cells that produce pro-tumorigenic cytokines, including IL-6 and TNF. Moreover, delivery of miR-122 to a MYC-driven mouse model of HCC strongly inhibited tumorigenesis, further supporting the tumor suppressor activity of this miRNA. These findings reveal critical functions for miR-122 in the maintenance of liver homeostasis and have important therapeutic implications, including the potential utility of miR-122 delivery for selected patients with HCC and the need for careful monitoring of patients receiving miR-122 inhibition therapy for HCV.


Related Papers

No related papers found

Powered by citation graph analysis